Healthcare M&A in the UAE: Regulatory Considerations

Mergers and acquisitions in the UAE healthcare sector involve strict regulation, several licensing authorities and sector-specific restrictions that shape how deals are structured.

By Nour Attorneys / 22 August 2026

Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant

Healthcare M&A in the UAE: Regulatory Considerations

Mergers and acquisitions (M&A) in the UAE healthcare sector are complex for investors, operators and legal advisors. Strict regulation, several licensing authorities and sector-specific restrictions mean that every healthcare M&A transaction in the UAE needs a carefully planned structure.

Healthcare remains a strategic focus for economic diversification and private sector growth in the UAE, attracting significant capital into hospitals, clinics, pharmaceutical distribution and medical technology services. However, the regulatory environment for these investments is unforgiving of uninformed or superficial transaction planning.

This article sets out the main regulatory considerations that govern M&A activity in the UAE healthcare sector. It covers the licensing requirements of the Dubai Health Authority (DHA), the Health Authority - Abu Dhabi (HAAD) and the Ministry of Health and Prevention (MOH), together with foreign ownership restrictions and compliance obligations. It also explains practical approaches to managing risk in deal origination, due diligence and post-transaction corporate restructuring, and how Nour Attorneys helps clients plan and complete healthcare M&A transactions in the UAE.

Related Services: Explore our healthcare legal services and regulatory compliance services in the UAE for practical legal support in this area.

The Regulatory Landscape for Healthcare M&A in the UAE

The UAE healthcare sector is regulated through a three-part system of federal and emirate-level authorities. The Ministry of Health and Prevention (MOH) governs healthcare activities at the federal level, mainly affecting emirates such as Sharjah, Ajman and Ras Al Khaimah. Dubai and Abu Dhabi, by contrast, have their own regulators, the Dubai Health Authority (DHA) and the Health Authority - Abu Dhabi (HAAD), which enforce strict sector-specific licensing and operational rules.

These regulators apply licensing frameworks designed to protect the integrity and quality standards of the healthcare system. Licensing is not merely procedural. It involves a substantive review of clinical governance, facility standards, financial stability and compliance with Emirati healthcare policies.

Consequently, any M&A transaction involving healthcare providers must secure compliance with these licensing regimes to avoid revocation risks or operational disruption after the acquisition. Failure to secure or transfer the appropriate licenses can wipe out the commercial benefits of an acquisition.

The regulatory environment also places particular constraints on foreign investors. While recent reforms have expanded foreign ownership rights in UAE companies, healthcare entities remain subject to strict foreign ownership limitations and licensing conditions that may effectively restrict control or influence by non-UAE nationals. Working within these constraints requires careful legal structuring and a well-chosen ownership model that stays both compliant and commercially viable.

Fragmented Regulatory Jurisdictions and Their Impact

The uneven nature of UAE healthcare regulation is most visible in its fragmented jurisdictions. Because each emirate takes its own regulatory approach, transactions that cross emirate borders need tailored legal structuring.

For example, a healthcare provider operating in both Dubai and Abu Dhabi must secure separate licenses and comply with differing operational standards. This fragmentation complicates M&A deals where the target has operations in more than one emirate. Legal advisors must design cross-jurisdictional compliance strategies that prevent operational gaps and unexpected regulatory intervention.

The regulators also update their policies frequently, reflecting shifts in healthcare priorities and national strategic goals. This changing environment requires continuous monitoring and flexible transaction structuring to reduce enforcement risk. For instance, changes in DHA’s licensing fees or HAAD’s quality accreditation criteria may affect the financial viability of a target company after the acquisition, which makes legal planning before the deal essential.

DHA, HAAD and MOH Licensing: Complexities and Strategic Considerations

Licensing under the DHA, HAAD and MOH remains a cornerstone of regulatory compliance in healthcare M&A. Each authority enforces a comprehensive licensing regime that must be considered from the start of the deal through post-closing integration.

In Dubai, the DHA licensing regime requires healthcare providers to obtain facility licenses, professional licenses for healthcare practitioners and corporate licenses. DHA approvals are prerequisites before operations begin or ownership changes. The DHA’s licensing process involves a rigorous inspection of clinical standards, governance frameworks and financial soundness.

From an M&A perspective, transferring existing licenses or obtaining new ones after the acquisition may pose significant challenges. Transactions must include mechanisms to keep licenses valid without interruption, which often requires engaging with the DHA early to remove regulatory roadblocks.

Similarly, HAAD governs healthcare licensing in Abu Dhabi, with a focus on quality assurance and patient safety. HAAD’s licensing protocols include facility accreditation, practitioner registration and corporate entity licensing. The authority applies a rigorous scrutiny process to mergers or acquisitions, including background checks and compliance verification.

HAAD’s framework often requires detailed restructuring plans and operational blueprints to be submitted after the M&A transaction to confirm that compliance continues. Legal advisors must apply careful statutory interpretation and negotiate accommodations with the regulator so that licenses are transferred or reissued smoothly.

The MOH’s regulatory oversight, which applies primarily to the northern emirates, imposes parallel licensing requirements, including facility approvals and professional registrations. The MOH also enforces public health mandates that may affect the scope of operations after a merger. Unlike the DHA and HAAD, MOH licensing may follow a different administrative timeline and different procedures, which calls for tailored legal strategies to achieve compliance and limit regulatory risk.

Licensing Transferability and Operational Continuity

A critical complexity in healthcare M&A transactions is whether existing licenses can be transferred. Licensing authorities often treat licenses as non-transferable without explicit approval, which can create real barriers to completing a transaction smoothly.

For instance, the DHA typically requires the incoming shareholder or controlling entity to apply for a license transfer. This process may involve a re-evaluation of the healthcare facility’s compliance with standards and may take several months.

If the license transfer is not managed properly, healthcare services may have to stop temporarily, harming patient care and commercial viability. Legal teams should therefore build transaction timelines that allow for licensing approval periods and engage directly with regulators early in the process to avoid delays.

Authorities may also impose additional requirements after the transfer, such as enhanced clinical governance procedures or updated financial guarantees. These obligations require changes to operational and financial arrangements, and they should be anticipated during deal negotiations.

Practical Example: Licensing Challenges in a Multi-Emirate Acquisition

Consider a foreign investor acquiring a healthcare group with facilities in Dubai and Abu Dhabi. The investor must satisfy DHA and HAAD licensing requirements at the same time, and these may differ significantly. While the DHA may demand rigorous clinical audits before a license transfer, HAAD might require evidence of Emirati managerial participation. Without a coordinated legal strategy, the two approvals can arrive at different times, putting the transaction and operational continuity at risk.

In such cases, Nour Attorneys designs a phased acquisition plan. We coordinate with both regulators to align compliance submissions and negotiate conditional operational approvals to limit the risk of business disruption.

Foreign Ownership Restrictions in UAE Healthcare Companies

Foreign ownership restrictions were once a major obstacle to investing capital in the UAE healthcare sector. Foreign investors were limited to 49% ownership in UAE entities outside designated free zones, with the remaining 51% held by UAE nationals. That general requirement has since been removed, and 100% foreign ownership is now permitted for most mainland activities, subject to the list of activities of strategic impact and the relevant emirate’s activity schedule, while healthcare investment remains subject to sector-specific licensing and approval by the competent health authority.

The government maintains a restrictive regulatory attitude toward foreign control in healthcare, emphasizing Emirati participation and control in healthcare delivery and management. Consequently, foreign investors must structure ownership carefully, often using joint ventures or nominee arrangements with UAE nationals to comply with ownership restrictions without compromising operational control.

Licensing authorities may also impose ownership-related conditions as part of facility licensing, including requirements for Emirati managerial presence or board representation. These mandates require precise legal drafting and corporate governance frameworks to reduce the risk of regulatory non-compliance or future ownership disputes.

Nour Attorneys designs ownership and governance models that balance commercial objectives with regulatory compliance. This includes comprehensive due diligence to identify ownership-related red flags and corporate restructuring solutions to optimize ownership arrangements after the acquisition. Our mergers and acquisitions and corporate restructuring services help clients work through these regulatory barriers effectively.

Ownership Structures: Compliance Models for Healthcare Investors

To work within foreign ownership restrictions, healthcare investors often hold their ownership through one of several models:

Limited Liability Companies (LLCs) with UAE Nationals: The traditional model, in which at least 51% of shares were held by UAE nationals, is no longer required, though investors may still choose a local partner. Where they do, shareholders’ agreements may grant operational control despite a minority shareholding, though this carries risks if it is not legally secured.
Free Zone Entities: Certain healthcare activities may be carried out through free zone companies, allowing 100% foreign ownership. However, free zone companies face operational restrictions, including limitations on conducting business directly in the UAE mainland healthcare market.
Professional Service Companies: In some cases, healthcare practitioners form professional service companies with ownership primarily limited to licensed professionals. This complicates foreign investment structuring and requires precise legal planning.
Trust and Nominee Arrangements: While controversial and increasingly scrutinized, some investors use nominee shareholder arrangements to maintain control. Regulators view this model unfavorably and it carries compliance risks, so it requires careful risk management.

Legal and Compliance Risks of Ownership Structures

Ownership structures that do not align with regulatory expectations expose investors to enforcement action, including license revocation, fines and reputational damage. Licensing authorities may audit ownership arrangements periodically, and suspected nominee structures can trigger investigations.

Nour Attorneys therefore designs ownership models that combine shareholder agreements, governance charters and operational controls built to withstand regulatory scrutiny. We also advise on disclosure obligations and put compliance frameworks in place to ensure transparency and adherence to UAE healthcare laws.

Due Diligence and Contract Drafting in Healthcare M&A

Due diligence is a critical phase for closing information gaps and avoiding unwelcome surprises in healthcare M&A. Beyond standard corporate, financial and tax due diligence, healthcare transactions demand sector-specific investigation into regulatory compliance, licensing status, clinical governance and potential liabilities.

Nour Attorneys uses a multi-layered due diligence approach designed to uncover hidden regulatory risks, license irregularities and compliance gaps. This includes:

verifying the status and transferability of DHA, HAAD or MOH licenses;
assessing compliance with Emirati healthcare laws;
evaluating employment contracts; and
scrutinizing malpractice or litigation exposure.

Due diligence findings inform the negotiation of risk allocation provisions, indemnities and warranties, building contractual safeguards against unforeseen liabilities.

Contract drafting in healthcare M&A transactions must reflect sector-specific regulatory constraints. Share purchase agreements (SPAs), asset purchase agreements (APAs) and shareholder agreements must include clear provisions on licensing obligations, regulatory approvals, foreign ownership compliance and post-closing operational covenants. These provisions create contractual remedies and escalation mechanisms for resolving regulatory challenges.

Nour Attorneys’ contract drafting expertise ensures that transaction documents are sound and aligned with regulatory realities. Our drafting anticipates regulatory risks and includes specific clauses to address regulatory uncertainty, protecting the integrity of the transaction.

Due Diligence Focus Areas: Clinical and Regulatory Risks

A major source of risk in healthcare M&A lies in clinical governance and regulatory compliance. Due diligence must draw on specialized legal and medical expertise to assess:

Clinical Quality Standards: Review of accreditation documents, clinical protocols, incident reports and patient safety records to identify potential liabilities.
Compliance with Healthcare Laws: Verification of adherence to Emirati healthcare regulations, including pharmaceutical importation laws, data privacy for patient records and advertising restrictions.
Employment Law and Practitioner Licenses: Evaluation of healthcare practitioners’ licensing status and employment contracts to ensure continuity of care and avoid regulatory sanctions.
Litigation and Malpractice Claims: Analysis of ongoing or past claims to assess contingent liabilities and reputational risks.

Contractual Clauses for Risk Mitigation

To reduce regulatory risk after closing, healthcare M&A contracts commonly include:

Condition Precedent Clauses: Making the transaction conditional on successful license transfers or approvals.
Indemnity and Warranty Provisions: Protecting the buyer against undisclosed regulatory breaches or license irregularities.
Regulatory Cooperation Clauses: Obliging sellers to advise on compliance matters after closing, including license renewals or inspections.
Change of Control Notifications: Ensuring timely disclosure to licensing bodies and managing the related regulatory interactions.
Escrow Arrangements: Retaining part of the purchase price to cover potential regulatory penalties or liabilities discovered after closing.

Nour Attorneys tailors these contractual tools to the complexities of healthcare deals and the UAE regulatory environment.

Post-Acquisition Corporate Restructuring and Compliance

Completing an M&A transaction in the healthcare sector is only one phase. Post-acquisition corporate restructuring and compliance work are equally critical to sustaining operational continuity and regulatory adherence.

After an acquisition, entities often need reorganizing to align ownership, governance and operations with regulatory requirements. This may include re-registering licenses with the DHA, HAAD or MOH, restructuring corporate entities to meet foreign ownership limits, and redesigning governance frameworks to satisfy Emirati representation mandates.

Nour Attorneys designs tailored corporate restructuring solutions that put efficient compliance frameworks in place. Our processes are built to prevent regulatory intervention or license revocation, so that the acquired healthcare entity operates within the regulatory perimeter. Our corporate restructuring services fit with broader operational and strategic objectives to make regulatory transitions efficient.

Continuous compliance monitoring after the acquisition is essential to prevent enforcement action, including fines, license suspensions or operational shutdowns. Nour Attorneys provides compliance audits and regulatory advice to keep healthcare entities aligned with evolving UAE healthcare laws and regulations.

Governance: Emiratization and Board Composition

A key post-acquisition challenge is compliance with Emiratization policies and governance mandates. Licensing authorities often require a minimum level of Emirati representation in management or on boards of directors. Designing governance frameworks that meet these requirements while keeping operations efficient requires precise legal work.

For example, the DHA may mandate that certain key managerial positions be held by Emirati nationals with relevant healthcare experience. HAAD might require Emirati participation in supervisory boards. These mandates can catch out investors unfamiliar with local policies, so governance solutions should be put in place early to reduce regulatory risk.

Nour Attorneys drafts shareholder agreements and board charters that define roles, delegation of authority and decision-making protocols to accommodate these mandates without compromising the investor’s strategic objectives.

Compliance Training and Policy Updates

Post-acquisition compliance goes beyond structural changes. It includes day-to-day adherence to healthcare laws, data privacy regulations and anti-bribery standards. Institutions must run ongoing compliance training programs for staff and management, aligned with regulatory expectations.

Regulatory authorities increasingly conduct unannounced audits and inspections, which makes internal compliance programs vital to reducing enforcement risk. Nour Attorneys prepares compliance manuals and training materials tailored to the healthcare sector’s particular challenges in the UAE, helping clients maintain a defensible compliance position.

Additional Legal Considerations in UAE Healthcare M&A

Intellectual Property and Technology Transfer

Healthcare M&A transactions frequently involve significant intellectual property (IP) assets, including proprietary medical technologies, software platforms and pharmaceutical formulations. The UAE’s IP laws, including patent and trademark protections, vary in enforcement rigor and registration requirements.

Investors must carry out IP due diligence to verify ownership, registration status and potential infringement risks. Transferring IP rights after the acquisition may require separate filings with the UAE Ministry of Economy and coordination with free zone authorities if the IP is held in a free zone.

Technology transfer agreements, which are often part of healthcare operations involving imported medical devices or pharmaceuticals, must also comply with UAE import regulations and customs laws. Non-compliance risks penalties and supply chain disruption.

Data Protection and Patient Privacy

The healthcare sector handles sensitive personal data, which is regulated by the UAE’s data protection laws, including the Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data. M&A transactions must include rigorous data privacy due diligence to identify risks related to how patient data is handled, stored and transferred.

Acquiring a healthcare entity involves transferring databases and health records, which requires compliance with consent requirements, data localization mandates and cybersecurity standards. If data transfer arrangements are not compliant, acquirers can face regulatory action and reputational damage.

Competition Law and Antitrust Considerations

Although the UAE does not have a comprehensive federal competition law, the UAE Competition Law (Federal Law No. 4 of 2012) and certain emirate-level regulations impose restrictions on anti-competitive practices. Healthcare M&A deals involving significant market shares may attract scrutiny from authorities seeking to prevent monopolistic practices.

Legal advisors should carry out competition risk assessments and, where appropriate, notify regulatory bodies to avoid potential enforcement action. This is particularly relevant in pharmaceutical distribution or specialized medical services, where market concentration could raise concerns.

Conclusion

Healthcare M&A transactions in the UAE demand a strategic, legally precise and operationally rigorous approach. The regulatory environment is complex, with several licensing authorities, demanding regulatory regimes and particular constraints on foreign ownership. Successful healthcare M&A requires comprehensive legal expertise to structure compliant transactions, design ownership and governance arrangements, and manage regulatory risk.

Nour Attorneys brings deep sector-specific knowledge and legal precision to M&A transactions that withstand regulatory scrutiny and deliver sustainable commercial value. By combining our expertise in mergers and acquisitions, due diligence, contract drafting and corporate restructuring, we build legal frameworks that support compliance, operational continuity and strategic success in the UAE healthcare sector.

Disclaimer

This article is for informational purposes only and does not constitute legal advice.

Related Legal Services

Contact Nour Attorneys

To plan the legal strategy for your healthcare M&A transaction in the UAE, contact Nour Attorneys for authoritative guidance tailored to your needs.

Visit our Mergers and Acquisitions practice page or contact us directly.

Additional Resources

Explore more of our insights on related topics: